Form 8-K - Current report:
SEC Accession No. 0001641172-25-019844
Filing Date
2025-07-16
Accepted
2025-07-16 09:28:08
Documents
14
Period of Report
2025-07-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38441
2 EX-99.1 ex99-1.htm EX-99.1 10545
3 GRAPHIC ex99-1_001.jpg GRAPHIC 34239
  Complete submission text file 0001641172-25-019844.txt   264609

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE qlgn-20250716.xsd EX-101.SCH 3008
5 XBRL LABEL FILE qlgn-20250716_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE qlgn-20250716_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3691
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 251126290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)